Sanofi Reports long-term follow-up Data for Evolocumab in Hypertension

Sanofi today announced long-term follow-up results for evolocumab in patients with hypertension. The study demonstrated that evolocumab demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of hypertension and support the continued development of evolocumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.